ALK and ROS1

ALK and ROS1: what it means for you

Does your report say “ALK-positive” or “ROS1-positive”? Here is what the gene fusion means, which tablets are authorised in the EU and why the brain is checked.

  • 4 min read
  • Updated 17 November 2026

Most important in brief

  • ALK and ROS1 are gene fusions in the tumour. They are not inherited.
  • ALK is found in about 3 to 5 in 100 people with NSCLC, ROS1 in about 1 to 2 in 100, often younger people and non-smokers.
  • The first treatment is a targeted tablet, often for years.
  • The brain is checked regularly with MRI.
  • After surgery, an ALK tablet can lower the risk of return.

What does ALK-positive mean?

In the tumour, two genes have become joined into one new gene. This is called a gene fusion. The new gene keeps sending the “grow” signal. Your report then says “ALK-positive” or “ALK fusion”, sometimes with the partner gene, for example EML4-ALK.

The fusion arises in the tumour and is not inherited. There are tablets that switch this signal off very precisely. Many people take them for years.

How common is it?

ALK is found in about 3 to 5 in 100 people with NSCLC, almost always in adenocarcinoma. People affected are younger on average, and many never or rarely smoked (ESMO). That is why every advanced NSCLC is tested for it, smokers included.

The first treatment for advanced disease

The first treatment is an ALK tablet, not chemotherapy or immunotherapy. Options authorised in the EU include:

TabletGood to know
Alectinib
Twice a day. Also works in the brain (EMA).
Brigatinib
Once a day, with a lower starting dose in the first week (EMA).
Lorlatinib
Once a day. Works well in the brain. Blood fats are monitored (EMA).
Older ALK tablets
e.g. crizotinib. Still used, for example when newer ones are not available.

Which tablet fits also depends on side effects, your daily life and availability in your country. No ranking; simplified from ESMO and Onkopedia.

Why the brain is checked

With ALK-positive lung cancer, the cancer spreads to the brain more often than in other forms. That is why a brain MRI is part of the start and of check-ups. The newer ALK tablets reach the brain well. Radiotherapy is then often not needed.

In earlier stages

After surgery, an ALK tablet can lower the risk of the cancer coming back. Alectinib is authorised for this in the EU, for up to two years (EMA). That is why the ALK test matters before or after surgery too.

For ROS1 there is no authorised tablet yet for the time after surgery. Ask whether a trial could fit. Before surgery, with ALK and ROS1, chemotherapy without immunotherapy is usually given.

When the tablet stops working

Often after years, the tumour finds a way around the tablet. A new test from tissue or blood shows which change has been added. Which tablet can work next depends on it.

  • Another ALK tablet, e.g. lorlatinib, if not given yet.
  • Platinum chemotherapy, often with pemetrexed.
  • Radiotherapy to single spots while the tablet continues.
  • Clinical trial with new ALK medicines.

ROS1: very similar to ALK

ROS1 is also a gene fusion. It is rarer than ALK and affects similar people. Here too, the first treatment is usually a tablet, and the brain is checked too.

ROS1 in lung cancer

Gene fusionin about 1 to 2 in 100 people with NSCLC

Like ALK: a gene fusion with a constant signal. Targeted tablets as the first treatment.

First treatment
ROS1 tablet.e.g.oror
Later
Another ROS1 tablet, or chemotherapy.e.g.

EU authorisation: EMA crizotinib, EMA entrectinib, EMA repotrectinib

Living with the tablets

Each tablet has its own side effects. Common ones are constipation, fluid retention, muscle pain, weight gain, raised blood fats and, with some tablets, changes in mood or concentration. Tell your team early. A lower dose often helps without losing the effect.

Many people with ALK live with the disease for a long time, in the middle of work and family life. Support for this is under Living with it and Community.

Questions about ALK and ROS1

  • Why ask?

    ALK and ROS1 are treated with different tablets.

  • Why ask?

    The tablets differ in side effects and in how well they work in the brain.

  • Why ask?

    This differs from country to country.

  • Why ask?

    ALK often spreads to the brain; regular MRIs find spots early.

  • Why ask?

    With ALK, a tablet after surgery can clearly lower the risk of relapse.

Sources

  1. ESMO Living Guideline: oncogene-addicted metastatic NSCLC
  2. Onkopedia: Lungenkarzinom, nicht-kleinzellig (NSCLC)
  3. EMA: EPAR alectinib
  4. EMA: EPAR brigatinib
  5. EMA: EPAR lorlatinib
  6. EMA: EPAR crizotinib
  7. EMA: EPAR entrectinib
  8. EMA: EPAR repotrectinib

All sources last checked on 12 November 2026, unless another date is given.